Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs GameStop Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.72 (market cap $9.43B), while GameStop Corp. trades at $18.52 (market cap $8.44B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and GameStop Corp. are close in size by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| BIO | GME | |
|---|---|---|
Market Cap | $9.43B | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $27.69 |
52-Week Low | $241.71 | $18.79 |
Enterprise Value | $9.18B | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
GME trades at $18.79, down 1.93% today, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings beats and a net income margin of 20.45% highlight improving profitability, though revenue declined to $3.82B in 2025. News indicates potential shifts in the proposed eBay acquisition strategy, moving toward a partnership instead of a full takeover.
The outlook is mixed: strong earnings momentum and low debt-to-asset ratio of 0.28 support upside, but bearish analyst consensus (16.67% buy) and revenue contraction pose risks. Investors face dilution concerns from a $1.4B debt-for-stock swap, while collectibles growth offers opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
